Drug Profile
Research programme: peroxisome proliferator activated receptor agonists - Albireo Pharma
Latest Information Update: 06 Mar 2023
Price :
$50
*
At a glance
- Originator Albireo AB
- Developer Albireo Pharma
- Class
- Mechanism of Action Peroxisome proliferator-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 02 Mar 2023 Albireo Pharma has been acquired by Ipsen
- 28 Jan 2019 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in Sweden
- 18 Dec 2014 Preclinical trials in Inflammatory bowel disease in Sweden (unspecified route)